Clinically, high levels of expression of ILK and YAP are correlated with poor prognosis in breast cancer [64,65] and glioma [66], while heightened expression of an ETAR/ILK/YAP/AP-1/ZEB1 gene signature is correlated with significantly shortened survival in a cohort of SOC patients [67]. The gene discussed is ILK; the disease is breast carcinoma.